IP Library Granted Patent US 10,945,419
Granted Patent B2
US 10,945,419 · App. 16/435,243 · Granted Mar 16, 2021

Genetically modified non-human animal with human or chimeric GITR

Inventors: Yuelei Shen (Beijing, CN); Yanan Guo (Beijing, CN); Yang Bai (Beijing, CN); Jiawei Yao (Beijing, CN); Rui Huang (Beijing, CN); Lei Zhao (Beijing, CN); Meiling Zhang (Beijing, CN)
Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
A01K67/0278A61K49/0008A01K2207/15A01K2217/075A01K2227/105A01K2267/0331
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,945,419
App. No.
16/435,243
Granted
Mar 16, 2021
Kind
B2
Abstract

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) glucocorticoid-induced TNFR-related protein (GITR), and methods of use thereof.

Claims (25)

1. A genetically-modified, non-human mammal whose genome comprises at least one chromosome comprising a replacement of a portion of the endogenous GITR gene with a portion of the human GITR gene, wherein the replacement creates a sequence encoding a humanized GITR protein comprising a humanized GITR extracellular region operably linked to an endogenous regulatory element at the endogenous GITR gene locus in the at least one chromosome, wherein the mammal detectably expresses the humanized GITR protein on the surface of activated T-cells.

2. The non-human mammal of claim 1 , wherein the humanized GITR protein comprises an amino acid sequence that is at least 70% identical to SEQ ID NO: 23.

3. The non-human mammal of claim 1 , wherein the humanized GITR comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 27.

4. The non-human mammal of claim 1 , wherein the humanized GITR protein comprises an amino acid sequence that is at least 90% identical to amino acids 1-142 of SEQ ID NO: 23.

5. The non-human mammal of claim 1 , wherein the mammal is a rodent.

6. The non-human mammal of claim 1 , wherein the mammal is a mouse.

7. The non-human mammal of claim 1 , wherein the mammal does not express endogenous GITR protein.

8. The non-human mammal of claim 1 , wherein the non-human mammal is homozygous with respect to the sequence encoding the humanized GITR protein.

9. The non-human mammal of claim 1 , wherein the non-human mammal further comprises a sequence encoding an additional humanized protein.

10. The non-human mammal of claim 9 , wherein the additional humanized protein is programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Lymphocyte Activating 3 (LAG-3), B And T Lymphocyte Associated (BTLA), Programmed Cell Death 1 Ligand 1 (PD-L1), CD27, CD28, CD40, CD47, CD137, T-Cell Immunoreceptor With Ig And ITIM Domains (TIGIT), T-cell Immunoglobulin and Mucin-Domain Containing-3 (TIM-3), Signal regulatory protein a (SIRPα), or TNF Receptor Superfamily Member 4 (OX40).

11. The non-human mammal of claim 1 , wherein the endogenous GITR gene locus is modified by CRISPR with sgRNAs that target SEQ ID NO: 1 and SEQ ID NO: 11.

12. The non-human mammal of claim 1 , wherein the humanized GITR protein comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 27.

13. The non-human mammal of claim 1 , wherein the humanized GITR protein comprises SEQ ID NO: 23.

14. The non-human mammal of claim 1 , wherein the humanized GITR protein comprises SEQ ID NO: 27.

15. A genetically modified rodent or a progeny thereof, whose genome comprises a replacement of a portion of the endogenous GITR gene with a portion of the human GITR gene, wherein the replacement creates a sequence encoding a humanized GITR protein comprising a humanized extracellular region operably linked to an endogenous regulatory element at the endogenous GITR gene locus in the at least one chromosome, wherein the mammal detectably expresses the humanized GITR protein on the surface of activated T-cells, wherein the genetically modified rodent is made by a method comprising the steps of:

modifying genome of an embryo of a rodent by CRISPR with sgRNAs that target SEQ ID NO: 1 and SEQ ID NO: 11, wherein the portion of the endogenous GITR gene is replaced with the portion of the human GITR gene; and

transplanting the embryo to a recipient rodent to produce the genetically-modified rodent, whose genome comprises the replacement of the portion of the endogenous GITR gene with the portion of the human GITR gene.

16. The rodent of claim 15 , wherein the rodent is a mouse.

17. A genetically-modified, non-human mammal whose genome comprises at least one chromosome comprising a replacement of a portion of the endogenous GITR gene encoding the extracellular region of the endogenous GITR protein with a nucleic acid sequence encoding the corresponding portion of the extracellular region of the human GITR protein, wherein the mammal detectably expresses a humanized GITR protein on the surface of activated T-cells.

18. The non-human mammal of claim 17 , wherein the sequence encoding the humanized GITR is operably linked to an endogenous regulatory element at the endogenous GITR gene locus in the at least one chromosome.

19. The non-human mammal of claim 17 , wherein the non-human mammal is a rodent.

20. The non-human mammal of claim 17 , wherein the non-human mammal is a mouse.

21. The non-human mammal of claim 17 , wherein the non-human mammal does not express endogenous GITR.

22. The non-human mammal of claim 17 , wherein the humanized GITR extracellular region comprises an amino acid sequence that is at least 90% identical to amino acids 1-142 of SEQ ID NO: 23.

23. The non-human mammal of claim 17 , wherein the humanized GITR protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 27.

Assignments (3)
CHANGE OF NAME Recorded Jan 22, 2021
From: BEIJING BIOCYTOGEN CO., LTD
To: BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Reel/Frame 055087/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2019
From: SHEN, YUELEI; GUO, YANAN; BAI, YANG; YAO, JIAWEI; HUANG, RUI; ZHAO, LEI; ZHANG, MEILING
To: BEIJING BIOCYTOGEN CO., LTD.
Reel/Frame 050605/0703 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2019
From: SHEN, YUELEI; GUO, YANAN; BAI, YANG; YAO, JIAWEI; HUANG, RUI; ZHAO, LEI; ZHANG, MEILING
To: BEIJING BIOCYTOGEN CO., LTD.
Reel/Frame 050442/0557 →
Priority Claims (3)
CN 201710465493.X · Jun 19, 2017 · national
CN 201710872122.3 · Sep 25, 2017 · national
CN 201810623611.X · Jun 15, 2018 · national
Continuity (2)
Continuation PCTCN2018091844 · Jun 19, 2018
Related Publication 20190364861A1 · Dec 5, 2019